Definium Therapeutics, Inc.
DFTX
Rangering i aksjer
#3609
Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm... Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.
Aksjekurs
$35.22
Sist synkronisert: 2026-10-20
Markedsverdi
$4.73B
Endring (1 dag)
6.82%
Endring (1 år)
222.07%
Land
US
Handel Definium Therapeutics, Inc. (DFTX)
Kategori
Healthcare
Historikk for aksjesplitt for Definium Therapeutics, Inc. (DFTX)
Aksjen Definium Therapeutics, Inc. (symbol: DFTX) har gjennomgått totalt 0 aksjesplitt.
Den nyeste splittelsen skjedde Oct 21, 2026.
Én DFTX-aksje kjøpt før Oct 21, 2026 tilsvarer i dag 0 DFTX-aksjer.
Den nyeste splittelsen skjedde Oct 21, 2026.
Én DFTX-aksje kjøpt før Oct 21, 2026 tilsvarer i dag 0 DFTX-aksjer.
Liste over aksjesplitt
| År | Splitt | Multiplikator | Kumulativ multiplikator |
|---|---|---|---|
| Ikke nok data for de angitte datoene. | |||
Aksjesplitt for lignende selskaper eller konkurrenter
| Selskap | Antall aksjesplitt | Kumulativ multiplikator | Land |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
